Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darceline
- Development stage
- Phase 4
- Lead developer
- Yunnan Cancer Hospital and Affiliated Cancer Hospital of Guangxi Medical University
- Administration
- Oral
01
Overview
Darceline is an investigational pharmaceutical drug being studied for the treatment of breast cancer. Clinical trials are exploring its use in ER+/HER2+ early breast cancer and HR+ advanced breast cancer. It is administered orally, with a typical regimen involving continuous daily dosing for three weeks followed by a one-week rest period within a 28-day cycle. The specific mechanism of action for darceline has not been disclosed in the available information.
- Other names
- Dalxil
Beyond the preview
Go deeper on darceline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darceline.